Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Clinical Microbiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
PLoS One. 2020 Jul 30;15(7):e0236864. doi: 10.1371/journal.pone.0236864. eCollection 2020.
Combination therapy in the treatment of sepsis, especially the value of combining a β-Lactam antibiotic with an aminoglycoside, has been discussed. This retrospective cohort study including patients with sepsis or septic shock aimed to investigate whether one single dose of gentamicin at admittance (SGA) added to β-Lactam antibiotic could result in a lower risk of mortality than β-Lactam monotherapy, without exposing the patient to the risk of nephrotoxicity.
All patients with positive blood cultures were evaluated for participation (n = 1318). After retrospective medical chart review, a group of patients with community-acquired sepsis with positive blood cultures who received β-Lactam antibiotic with or without the addition of SGA (n = 399) were included for the analysis. Mean age was 74.6 yrs. (range 19-98) with 216 (54%) males. Sequential Organ Failure Assessment score (SOFA score) median was 3 (interquartile range [IQR] 2-5) and the median Charlson Comorbidity Index for the whole group was 2 (IQR 1-3). Sixty-seven (67) patients (17%) had septic shock. The 28-day mortality in the combination therapy group was 10% (20 of 197) and in the monotherapy group 22% (45 of 202), adjusted HR 3.5 (95% CI (1.9-6.2), p = < 0.001. No significant difference in incidence of acute kidney injury (AKI) was detected.
This retrospective observational study including patients with community-acquired sepsis or septic shock and positive blood cultures, who meet Sepsis-3 criteria, shows that the addition of one single dose of gentamicin to β-lactam treatment at admittance was associated with a decreased risk of mortality and was not associated with AKI. This antibiotic regime may be an alternative to broad-spectrum antibiotic treatment of community-acquired sepsis. Further prospective studies are warranted to confirm these results.
联合治疗在脓毒症的治疗中,尤其是联合使用β-内酰胺类抗生素和氨基糖苷类抗生素的价值,一直备受争议。本回顾性队列研究纳入了脓毒症或感染性休克患者,旨在探讨入院时单次给予庆大霉素(SGA)联合β-内酰胺类抗生素治疗是否比单纯使用β-内酰胺类抗生素治疗的患者死亡率更低,同时又不增加肾毒性风险。
所有血培养阳性的患者均进行了评估(n=1318)。经回顾性病历审查,纳入了一组血培养阳性的社区获得性脓毒症患者,这些患者接受了β-内酰胺类抗生素治疗,并根据是否加用 SGA 分为两组(n=399)。患者平均年龄为 74.6 岁(19-98 岁),其中 216 例(54%)为男性。序贯器官衰竭评估(SOFA)评分中位数为 3 分(四分位距 [IQR] 2-5),全组Charlson 合并症指数中位数为 2 分(IQR 1-3)。67 例(67%)患者发生感染性休克。联合治疗组 28 天死亡率为 10%(197 例中的 20 例),单药治疗组为 22%(202 例中的 45 例),调整后的 HR 为 3.5(95%CI 1.9-6.2,p<0.001)。未发现急性肾损伤(AKI)发生率的显著差异。
本回顾性观察性研究纳入了符合 Sepsis-3 标准的血培养阳性的社区获得性脓毒症或感染性休克患者,结果表明入院时给予β-内酰胺类抗生素加用单次剂量庆大霉素可降低死亡率,且与 AKI 无关。这种抗生素方案可能是治疗社区获得性脓毒症的广谱抗生素治疗的替代方案。需要进一步的前瞻性研究来证实这些结果。